PRIMO Phase 2 trial

October 10, 2019

Copiktra Receives FDA’s Orphan Drug Status for T-cell Lymphoma Treatment

News

The small molecule inhibitor Copiktra (duvelisib) has been given orphan status by the U.S. Food and Drug Administration (FDA) for the treatment of T-cell lymphoma, the therapy’s developer, Verastem Oncology, ... Read more

June 27, 2019June 27, 2019

Copiktra Induces Promising Clinical Activity in PTCL Patients, Phase 1 Trials Show

News

Copiktra (duvesilib) shows promising clinical activity in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), inducing responses in 44% to 57% of patients included in Phase 1 trials. The ... Read more

November 14, 2018

Verastem Advances Copiktra for Peripheral T-cell Lymphoma Under LLS Therapy Acceleration Program

News

Aiming to accelerate the development of Copiktra (duvelisib) for treatment of peripheral T-cell lymphoma (PTCL) — an aggressive type of non-Hodgkin’s lymphoma — Verastem has announced a collaboration with the Leukemia & Lymphoma Society (LLS). ... Read more